The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965), AHA-supported legislation that would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. Previously passed by the Energy and Commerce Committee, the bill could next move to the floor.
 
In other action yesterday, the Judiciary Committee approved bipartisan bills to strengthen the Federal Trade Commission’s ability to challenge anticompetitive pay-for-delay agreements in court (H.R. 2375); reduce incentives for brand name drug makers to interfere with the regulatory approval of generics and biosimilars (H.R. 2374); and require the FTC to study competition in the drug supply chain (H.R. 2376).

Related News Articles

Headline
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D…
Headline
Kansas Gov. Laura Kelly has reached agreement with Senate Republicans on a bipartisan proposal to expand Medicaid eligibility to low-income uninsured…
Headline
The Centers for Medicare & Medicaid Services has delayed 2020 private payer data reporting for the Clinical Diagnostic Test Payment System until 2021 for…
Headline
The Senate today voted 71-23 to pass legislation (H.R. 1865) funding the Department of Health and Human Services and other non-Defense agencies for fiscal…
Headline
The Food and Drug Administration today released a proposed rule that would allow states and other non-federal government entities to establish programs to…
Headline
The House today approved a $1.4 trillion spending package for fiscal year 2020. The bills include a number of key issues for hospitals and health systems…